Navigating the cell therapy partnership selection process can be complex. Here, I share the questions you should be asking to help you get it right.

We delve into the story behind Lonza’s collaboration with Asahi Kasei Bioprocess America.

How digitalization will revolutionize the way we develop and optimize bioprocesses.

The potential of the cell and gene therapies sector depends – partially – on the expertise of the transport and logistics partners that complement it.

Researchers demonstrate that complex data analysis paired with artificial intelligence can predict additional causes of Teratogenicity

Deputy editor Rob Coker recalls his trip to the labs of Caszyme, Vilnius, where he spoke with CEO Monika Paule about the potential of genome editing

The more we learn about the complexity of Alzheimer’s, the more we need to change the way we treat it

With new drugs showing promise for Alzheimer’s, is the drug development drought over?

Sitting Down With… Sharon L Rogers, AmyriAD CEO, Renowned drug developer, 2023 Power Lister, and Olympic figure skating official

A look at cGMP deviations in recent warning letters, including manufacturing conducted in corridors and equipment uncleaned for 14 years.